蛋白酶体抑制剂MG132对人子宫内膜癌HEC-1B和Ishikawa细胞增殖、凋亡和周期的影响  

Effects of Proteasome Inhibitor MG132 on Cell Proliferation,Apoptosis,and Cell Cycle in HEC-1B and Ishikawa Cells

作　　者：张勤[1] 黄娟[1] 李丹青[1] 何跃东[1] 

机构地区：[1]四川大学华西第二医院妇产科,成都610041

出　　处：《四川大学学报（医学版）》2012年第6期830-833,838,共5页Journal of Sichuan University(Medical Sciences)

基　　金：成都市科技计划项目(No.11DXYB191SF)资助

摘　　要：目的了解蛋白酶体抑制剂三肽基乙醛(Z-Leu-Leu-Leu-cho,MG132)抗人子宫内膜癌HEC-1B和Ishikawa细胞的活性,研究MG132治疗人子宫内膜癌的潜在应用价值。方法用不同浓度的MG132(0,0.2,0.5,1.0μmol/L)处理HEC-1B和Ishikawa细胞24h、48h,采用MTT法检测MG132对HEC-1B和Ishikawa细胞增殖的影响;应用流式细胞术分别检测0.5μmol/L MG132处理24h后两种细胞的凋亡率和细胞周期分布。结果 MG132能抑制HEC-1B和Ishikawa细胞增殖,在本研究浓度范围内MG132浓度增高对两种细胞的抑制作用增强(P<0.01),48h抑制作用强于24h(P<0.01),Ishikawa细胞对MG132的敏感程度大于HEC-1B细胞。MG132处理HEC-1B和Ishikawa细胞后凋亡率均增加(P=0.000),细胞周期分析显示HEC-1B细胞G2期细胞比例增加(P<0.05),Ishikawa细胞G1和G2细胞比例增加(P<0.05)。结论蛋白酶体抑制剂MG132对HEC-1B和Ishikawa细胞有增殖抑制、诱导凋亡和阻滞细胞周期的作用。MG132可能成为潜在的子宫内膜癌化疗药物。Objective To study the anti-cancer activities of Z-Leu-Leu-Leu-cho （MG132） against human endometrial carcinoma HEC-1B and Ishikawa cells and the potential of MG132 in human endometrial cancer therapy. Methods HEC-1B and Ishikawa cells were treated with MG132. Cell proliferation was assessed by MTT while cell apoptosis rate and cell-cycle distribution were assessed by flow cytometry. Results The proliferation of HEC-1B and Ishikawa cells was inhibited by MG132 and cell proliferation was significantly inhibited with the raised concentration of MG132 （P〈0. 01）, Ishikawa cells were more sensitive than HEC-1B cells to MG132. MG132 could induce the apoptosis of HEC-1B and Ishikawa cells （P = 0. 000）. Cell cycle analysis indicated that the percentage of HEC-1B cells was increased in G2 phase （P〈0.05） while Ishikawa cells＇ was increased in G1 and Gz phase （P^0.05）. Conclusion Proteasome inhibitor MG132 could inhibit the proliferation, promote cell apoptosis, and block the cell cycle of HEC-1B and Ishikawa ceils. MG132 may be a potential treatment for endometrial cancer.

关 键 词：三肽基乙醛 子宫内膜癌 增殖 凋亡 细胞周期 

分 类 号：R737.33[医药卫生—肿瘤]